Heart veh Bzb Liver Kidney Lung Supplementary figure 1. Bzb injections do not have morphologically detectable side effect in mice. Mice treated with either vehicle or Bzb injections were sacrificed at 4 weeks after focal radiation. Vital organs, such as heart, liver, kidney, and lung were harvested for paraffin sections followed by H&E staining. n=5 mice/group. Supplementary figure 2. MG132 does not affect gH2AX protein amounts in non-irradiated UMR 106 cells as shown by immunoblotting. Supplementary figure 3. MG132 does not affect Ku70 or DNA-PKc protein amounts in non- irradiated cells as shown by immunoblotting. Supplementary figure 4. Focal radiation and Bzb treatment do not alter trabecular bone structure and strength at 2 weeks. (A) Representative 3D µCT images of distal femoral trabecular bone from WT mice treated with either vehicle or Bzb injections at 2 weeks after focal radiation. n=4-5 mice/group. (B) MicroCT measurement of trabecular bone structural parameters. (C) Trabecular bone stiffness was measured by microCT and FEA. Supplementary figure 6. Bzb injections reduce bone marrow adiposity in the irradiated area. Representative images of Goldner trichrome-stained trabecular bone sections reveal bone marrow cellularity and adipocytes (asterisks) at 2 weeks post radiation. Note that bone marrow hematopoietic cells are almost completely recovered in bone, regardless of Bzb treatment, at this time point. Supplementary figure 5. Bzb treatment suppresses apoptosis of irradiated osteocytes.(A) Representative images of TUNEL+ osteocytes (green, pointed by arrows) in the trabecular bone at 2 weeks post-irradiation. (B) Quantification of the percentage of TUNEL+ osteocytes. b: p<0.01 R vs NR. $: p<0.01 Bzb vs veh. n=3 femurs/group.